Constraint-Aware Corrective Memory for Language-Based Drug Discovery Agents

TL;DR

CACM enhances language-based drug discovery by implementing precise set-level diagnosis and memory management, significantly improving success rates through better failure localization and correction strategies.

Contribution

Introduces CACM, a novel framework for drug discovery agents that uses protocol auditing and grounded diagnosis to improve decision accuracy and success rates.

Findings

CACM improves target success rate by 36.4% over baseline.

Set-level diagnosis enables precise failure localization.

Memory organization and compression enhance planning efficiency.

Abstract

Large language models are making autonomous drug discovery agents increasingly feasible, but reliable success in this setting is not determined by any single action or molecule. It is determined by whether the final returned set jointly satisfies protocol-level requirements such as set size, diversity, binding quality, and developability. This creates a fundamental control problem: the agent plans step by step, while task validity is decided at the level of the whole candidate set. Existing language-based drug discovery systems therefore tend to rely on long raw history and under-specified self-reflection, making failure localization imprecise and planner-facing agent states increasingly noisy. We present CACM (Constraint-Aware Corrective Memory), a language-based drug discovery framework built around precise set-level diagnosis and a concise memory write-back mechanism. CACM introduces protocol auditing and a grounded diagnostician, which jointly analyze multimodal evidence spanning task requirements, pocket context, and candidate-set evidence to localize protocol violations, generate actionable remediation hints, and bias the next action toward the most relevant correction. To keep planning context compact, CACM organizes memory into static, dynamic, and corrective channels and compresses them before write-back, thereby preserving persistent task information while exposing only the most decision-relevant failures. Our experimental results show that CACM improves the target-level success rate by 36.4% over the state-of-the-art baseline. The results show that reliable language-based drug discovery benefits not only from more powerful molecular tools, but also from more precise diagnosis and more economical agent states.